We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $9.40 in the latest trading session, marking a -3.09% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.7% for the day. At the same time, the Dow added 0.28%, and the tech-heavy Nasdaq gained 0.83%.
Shares of the vaccine maker witnessed a loss of 8.75% over the previous month, trailing the performance of the Medical sector with its gain of 3.23%, and the S&P 500's loss of 1.21%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. In that report, analysts expect Novavax to post earnings of -$0.33 per share. This would mark year-over-year growth of 46.77%. Our most recent consensus estimate is calling for quarterly revenue of $50.61 million, down 28.15% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$0.38 per share and a revenue of $377.43 million, demonstrating changes of -114.73% and -66.4%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Novavax. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 16.88% upward. As of now, Novavax holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 100, placing it within the top 41% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Novavax (NVAX - Free Report) closed at $9.40 in the latest trading session, marking a -3.09% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.7% for the day. At the same time, the Dow added 0.28%, and the tech-heavy Nasdaq gained 0.83%.
Shares of the vaccine maker witnessed a loss of 8.75% over the previous month, trailing the performance of the Medical sector with its gain of 3.23%, and the S&P 500's loss of 1.21%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. In that report, analysts expect Novavax to post earnings of -$0.33 per share. This would mark year-over-year growth of 46.77%. Our most recent consensus estimate is calling for quarterly revenue of $50.61 million, down 28.15% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$0.38 per share and a revenue of $377.43 million, demonstrating changes of -114.73% and -66.4%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Novavax. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 16.88% upward. As of now, Novavax holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 100, placing it within the top 41% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.